Your search history is turned on.
Date: May 1, 2024 Jurisdictions: All jurisdictions
STATEMENT OF EXECUTIVE COMPENSATION The following disclosure complies with the requirements of Form 51-102F6V Statement of Executive Compensation Venture Issuers, for Entheon Biomedical Corp. (the Company) during its fiscal year ending November 30, 2023. For the purposes of this statement, the following definitions apply: compensation securities includes s...
Date: April 29, 2024 Jurisdictions: All jurisdictions
1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Soo-Whan Kim, Interim Chief Financial Officer of Entheon Biomedical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Entheon Biomedical Corp., (the issuer) for the interim period ended...
1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Timothy Ko, Chief Executive Officer of Entheon Biomedical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Entheon Biomedical Corp. (the issuer) for the interim period ended February 2...
ENTHEON BIOMEDICAL CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED FEBRUARY 29, 2024 AND FEBRUARY 28, 2023 (Expressed in Canadian Dollars) (Unaudited) NOTICE OF NO AUDITOR REVIEW OF ...
ENBI MDA August 31 2022 v3 (D0423255.DOCX;2) ENTHEON BIOMEDICAL CORP. MANAGEMENT DISCUSSION AND ANALYSIS For the three months ended February 29, 2024 and February 28, 2023 ENTHEON BIOMEDICAL CORP. MANAGEMENT DISCUSSION AND ANALYSIS For the three months en...
Date: April 22, 2024 Jurisdictions: British Columbia, Ontario
Create report of exempt distribution (Form 45-106F1) Form 45-106F1 Report of Exempt Distribution ITEM 1 - REPORT TYPE New report Amended report If amended, provide filing date of report that is being amended. (YYYY-MM-DD) ITEM 2 - PARTY CERTIFYING THE REPORT Indicate the party certifying the report (select only one). For guidance regarding whether an ...
Date: April 19, 2024 Jurisdictions: All jurisdictions
Form 51-102F3 1 Form 51-102F3 Material Change Report 1. Name and Address of Company Entheon Biomedical Corp. Suite 720 - 999 W Broadway Street Vancouver, BC V5Z 1K5 (the Company) 2. Dates of Material Change(s) April 18, 2024 3. News Release(s) New...
Form 51-102F3 1 Form 51-102F3 Material Change Report 1. Name and Address of Company Entheon Biomedical Corp. Suite 720 - 999 W Broadway Street Vancouver, BC V5Z 1K5 (the Company) 2. Dates of Material Change(s) March 1, 2024 3. News Release(s) News...
Entheon - News Release re Closing of Asset Purchase Agreement (D0372956-4).DOCX Entheon Biomedical Announces Closing of Private Placement Financing VANCOUVER, BC, April 18, 2024 Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) (Entheon" or the Company) is pleased to announce that, further to its news rel...
Date: April 11, 2024 Jurisdictions: All jurisdictions
Entheon - News Release re Closing of Asset Purchase Agreement (D0372956-4).DOCX NOT FOR DISTRIBUTION IN THE UNITED STATES Entheon Biomedical Announces Private Placement Financing VANCOUVER, BC, April 11, 2024 Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) (Entheon" or the Company) announces that it...